ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 160

Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia

Robert S. Katz1 and Jessica L. Polyak2, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates S.C., Chicago, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We have found that patients with a variety of rheumatic diseases who have concomitant fibromyalgia more frequently fail therapies for the underlying inflammatory rheumatic disease and osteoarthritis. Based on the 2010 ACR criteria for the diagnosis of fibromyalgia, a screening form was developed at the time of the study for accurate diagnosis. The screening assessment form is filled in by patients. It includes 19 pain areas as well as questions concerning sleep, energy, cognition, headache, abdominal pain, and depression. Adding this fibromyalgia screening questionnaire to the patient’s initial visit can also help validate the diagnosis in the minds of patients and also clinicians. We had patients in a rheumatology office practice complete this diagnostic form.

Methods: There are 19 pain areas listed. Patients checked a box next to the areas of pain during the last 7 days and replied to questions for the other symptoms- sleep (0-3), energy (0-3), cognition (0-3), and abdominal pain (0-1), headaches (0-1) and depression (0-1). A score of 12 and above is consistent with fibromyalgia.

Results: 60 patients with various rheumatic diseases, but excluding primary fibromyalgia, filled out the assessment form developed for the 2010 ACR diagnostic criteria. In those patients with an underlying inflammatory rheumatic disease diagnosis, without known fibromyalgia, 14 (23.3%) had a finding of 12 or more points using the fibromyalgia diagnostic screening form.

Conclusion: The fibromyalgia screening form developed in conjunction with the ACR 2010 criteria for fibromyalgia diagnosis can be quite helpful in determining the presence of concomitant fibromyalgia. 23.3% of a group of patients with inflammatory arthritis, lupus, and osteoarthritis also had fibromyalgia, according to the screening form results.

This form can be used to suggest the possibility of concomitant fibromyalgia in patients with other rheumatic diseases. Concomitant fibromyalgia and an inflammatory rheumatic disease may be a reason for the failure of biologic modifier and other therapy aimed at reducing pain and improving global well-being.


Disclosure: R. S. Katz, None; J. L. Polyak, None.

To cite this abstract in AMA style:

Katz RS, Polyak JL. Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/fibromyalgia-screening-form-in-the-diagnosis-of-concomitant-fibromyalgia-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibromyalgia-screening-form-in-the-diagnosis-of-concomitant-fibromyalgia-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology